These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3309367)

  • 1. Monocyte cytolytic factor in promoting monocyte-mediated lysis of bladder cancer cells by bacillus Calmette-Guerin.
    Catalona WJ
    J Urol; 1987 Oct; 138(4):866. PubMed ID: 3309367
    [No Abstract]   [Full Text] [Related]  

  • 2. Monocyte cytolytic factor in promoting monocyte-mediated lysis of bladder cancer cells by bacillus Calmette-Guerin.
    Nakamura K; Chiao JW; Nagamatsu GR; Addonizio JC
    J Urol; 1987 Oct; 138(4):867-70. PubMed ID: 3116282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monocyte-mediated cytotoxicity on bladder cancer cells in vitro and its implication in the treatment of bladder cancer patients with bacillus Calmette-Guérin.
    Nakamura K
    Keio J Med; 1984 Nov; 33(4):185-99. PubMed ID: 6530875
    [No Abstract]   [Full Text] [Related]  

  • 4. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
    Miyazaki J; Onozawa M; Takaoka E; Yano I
    Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacillus Calmette-Guérin for upper tract urothelial cancer: is there a role?
    Rastinehad AR; Smith AD
    J Endourol; 2009 Apr; 23(4):563-8. PubMed ID: 19335155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
    J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
    Ratliff TL; Palmer JO; McGarr JA; Brown EJ
    Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
    Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
    J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
    Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
    J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
    Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
    J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus Calmette-Guerin in the management of bladder cancer.
    Droller MJ
    J Urol; 1986 Feb; 135(2):331-3. PubMed ID: 3511288
    [No Abstract]   [Full Text] [Related]  

  • 16. Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.
    Pryor K; Goddard J; Goldstein D; Stricker P; Russell P; Golovsky D; Penny R
    Br J Cancer; 1995 Apr; 71(4):801-7. PubMed ID: 7710947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacillus of Calmette and Guerin modulates nuclear factor kappa beta in two urothelial carcinoma cell lines.
    Liou LS; Sadhukhan PC; Bandyopadhyay SK; Rackley RR
    Adv Exp Med Biol; 2003; 539(Pt B):599-621. PubMed ID: 15176315
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of LFA-1 in the lysis of bladder cancer cells by bacillus Calmette-Guérin and interleukin 2-activated killer cells.
    Suttmann H; Jocham D; Böhle A; Brandau S
    Urol Res; 2002 Sep; 30(4):233-9. PubMed ID: 12202941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy.
    DiPaola RS; Lattime EC
    J Urol; 2007 Nov; 178(5):1840-1. PubMed ID: 17868741
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhancement of bacillus Calmette-Guerin attachment to the urothelium by removal of the rabbit bladder mucin layer.
    Badalament RA; Franklin GL; Page CM; Dasani BM; Wientjes MG; Drago JR
    J Urol; 1992 Feb; 147(2):482-5. PubMed ID: 1732628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.